TY  - JOUR
AU  - Pfütze, Katrin
AU  - Benner, Axel
AU  - Hoffmeister, Michael
AU  - Jansen, Lina
AU  - Yang, Rongxi
AU  - Bläker, Hendrik
AU  - Herpel, Esther
AU  - Ulrich, Alexis
AU  - Ulrich, Cornelia M
AU  - Chang-Claude, Jenny
AU  - Brenner, Hermann
AU  - Burwinkel, Barbara
TI  - Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
JO  - Genomics
VL  - 106
IS  - 6
SN  - 0888-7543
CY  - San Diego, Calif.
PB  - Academic Press
M1  - DKFZ-2017-03324
SP  - 348 - 354
PY  - 2015
AB  - DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
KW  - Antimetabolites, Antineoplastic (NLM Chemicals)
KW  - Cell Adhesion Molecules (NLM Chemicals)
KW  - GPI-Linked Proteins (NLM Chemicals)
KW  - Hyal2 protein, human (NLM Chemicals)
KW  - Hyaluronoglucosaminidase (NLM Chemicals)
KW  - Fluorouracil (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26453961
DO  - DOI:10.1016/j.ygeno.2015.10.002
UR  - https://inrepo02.dkfz.de/record/127299
ER  -